Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

669 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials.
Tanizawa Y, Kaku K, Araki E, Tobe K, Terauchi Y, Utsunomiya K, Iwamoto Y, Watada H, Ohtsuka W, Watanabe D, Suganami H; Tofogliflozin 004 and 005 Study group. Tanizawa Y, et al. Among authors: kaku k. Expert Opin Pharmacother. 2014 Apr;15(6):749-66. doi: 10.1517/14656566.2014.887680. Epub 2014 Feb 11. Expert Opin Pharmacother. 2014. PMID: 24512053 Clinical Trial.
Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study.
Kaku K, Watada H, Iwamoto Y, Utsunomiya K, Terauchi Y, Tobe K, Tanizawa Y, Araki E, Ueda M, Suganami H, Watanabe D; Tofogliflozin 003 Study Group. Kaku K, et al. Cardiovasc Diabetol. 2014 Mar 28;13:65. doi: 10.1186/1475-2840-13-65. Cardiovasc Diabetol. 2014. PMID: 24678906 Free PMC article. Clinical Trial.
Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus.
Haneda M, Seino Y, Inagaki N, Kaku K, Sasaki T, Fukatsu A, Kakiuchi H, Sato Y, Sakai S, Samukawa Y. Haneda M, et al. Among authors: kaku k. Clin Ther. 2016 Jan 1;38(1):66-88.e20. doi: 10.1016/j.clinthera.2015.10.025. Epub 2015 Dec 22. Clin Ther. 2016. PMID: 26718606 Free article. Clinical Trial.
Efficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients With Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Data From 52-Week Phase III Trials.
Sakai S, Kaku K, Seino Y, Inagaki N, Haneda M, Sasaki T, Fukatsu A, Kakiuchi H, Samukawa Y. Sakai S, et al. Among authors: kaku k. Clin Ther. 2016 Apr;38(4):843-862.e9. doi: 10.1016/j.clinthera.2016.01.017. Epub 2016 Mar 25. Clin Ther. 2016. PMID: 27021608 Free article. Clinical Trial.
Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial.
Terauchi Y, Tamura M, Senda M, Gunji R, Kaku K. Terauchi Y, et al. Among authors: kaku k. Diabetes Obes Metab. 2017 Oct;19(10):1397-1407. doi: 10.1111/dom.12957. Epub 2017 Jul 13. Diabetes Obes Metab. 2017. PMID: 28371205 Free PMC article. Clinical Trial.
669 results